NEW YORK (GenomeWeb News) – Myriad Genetics said today that Mammography Reporting Systems, a breast cancer tracking and reporting software service, will use risk markers to identify patients who might benefit from Myriad's BRACAnalysis test.
Myriad said that MRS will incorporate risk factors for hereditary breast cancer risk in its software, enabling more physicians at mammography screening centers to identify patients who may benefit from the Myriad test.
"Identifying high-risk patients will result in even better patient care," MRS CEO Mark Morris said in a statement. "Working in concert with the patients' primary care physician, radiologists who use
MRS software can identify and recommend increased surveillance and BRCA gene testing for those patients who are at high risk."